TheraCryf PLC
TCF
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,136.60 | 15.10 | 0.17% |
CAC 40 | 7,966.95 | 71.01 | 0.90% |
DAX 40 | 24,113.62 | 232.90 | 0.98% |
Dow JONES (US) | 46,375.36 | 22.53 | -0.05% |
FTSE 100 | 9,446.43 | 96.00 | 1.03% |
HKSE | 26,855.56 | 232.68 | 0.87% |
NASDAQ | 22,694.54 | 34.53 | 0.15% |
Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
S&P 500 | 6,692.03 | 3.57 | 0.05% |
S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |